Streamlined Oncology Calculators & Survival Analysis
For clinical decision & research support.
PLCOm2012 Lung Cancer Risk
PLCOm2012 workflow estimates 6-year lung cancer risk and adds LDCT screening context using model-based and USPSTF-style criteria.
Peritoneal Carcinomatosis Index (PCI)
Calculate the Sugarbaker Peritoneal Cancer Index by recording the largest visible implant in each of 13 regions.
IPSET-Thrombosis (Essential Thrombocythemia)
Calculate both the original 2012 IPSET-Thrombosis score and the revised 2015 IPSET-Thrombosis category for WHO-defined essential thrombocythemia.
Leibovich Score (RCC)
The 2003 Leibovich score estimates metastasis-free survival after nephrectomy for non-metastatic clear-cell renal cell carcinoma.
Van Nuys Prognostic Index (USC-VNPI)
The age-modified 2003 USC-VNPI is a historical four-domain local-recurrence score for pure DCIS after definitive excision.
Brock (PanCan) Nodule Risk
Brock PanCan model estimates lung cancer probability in pulmonary nodules detected on CT to guide biopsy versus surveillance decisions.
Myeloma R2-ISS and IMWG Frailty Panel
Separate original 2022 R2-ISS disease-risk and 2015 IMWG Frailty interpretations for pretreatment newly diagnosed symptomatic multiple myeloma.
Febrile Neutropenia Triage
Parallel MASCC and CISNE risk evidence with strict population and safety gates.
Palliative Survival Prediction
Independent PaP and PPI component results with no combined prognostic score.
Liver & HCC Parallel Results Panel
Six liver/HCC results from 18 clinical inputs and one concise scope confirmation, with component-specific availability.
Lung Nodule Malignancy Risk Panel
Displays independent Brock, Mayo, and Herder pulmonary-nodule model results with model-specific applicability; it does not create a combined risk estimate.
CAPRA + Epstein Prostate Risk Panel
Parallel source-locked display of the original UCSF-CAPRA score and historical Johns Hopkins Epstein T1c pretreatment criteria.
Renal Cell Carcinoma (RCC) Prognosis Panel
Side-by-side IMDC (Heng) and historical MSKCC (Motzer 2002) prognostic classifications for metastatic RCC.
DLBCL Prognosis Panel
Five separate source-locked prognostic interpretations for adults with newly diagnosed de novo DLBCL at pretreatment baseline.
ECOG Performance Status
Document the official ECOG performance status grade from 0 to 5.
Body Surface Area (BSA)
Estimate body surface area from height and weight using the Du Bois or Mosteller formula; treatment dosing remains protocol- and clinician-specific.
DPYD / DPD Fluoropyrimidine Activity Score
Interpret a DPYD activity score reported by a validated laboratory for 5-FU, capecitabine, or tegafur treatment planning.
Carboplatin Calvert Formula Dose
Calculate total carboplatin dose from target AUC and an explicitly selected kidney-function method.
Karnofsky Performance Status (KPS)
Document Karnofsky Performance Status with the 11-grade scale from 100 through 0.
WHO Performance Status
Document adult WHO Performance Status with the official five-grade scale from 0 to 4.
Charlson Comorbidity Index
Original 1987 Charlson comorbidity index with the 1994 age extension, reported as separate comorbidity, age, and combined totals.
RMH Score (Phase I Trials)
Original 2008 Royal Marsden Hospital three-factor prognostic score for adults with advanced solid tumors evaluated for phase-I oncology trials.
Khorana Score (VTE Risk)
Original Khorana score for early chemotherapy-associated VTE risk in ambulatory adults.
Culine CUP Prognostic Model (2002)
Applies the original 2002 Culine final two-factor prognostic model for adults with confirmed unfavorable carcinoma of unknown primary.
Lee 2019 Pretreatment Plasma EBV-DNA-Augmented NPC RPA Classification
Interprets externally assigned AJCC/UICC eighth-edition T/N/M and compatible pretreatment plasma EBV-DNA using the source-specific Lee 2019 NPC RPA branches.
Fistula Risk Score (FRS)
Original 2013 Callery Model III intraoperative Fistula Risk Score after pancreaticoduodenectomy.
JGCA eCura Classification After Endoscopic Resection (2021)
Classifies post-EMR/ESD histopathologic curability as eCura A, B, C-1, or C-2 using the JGCA 2021 sixth edition.
Modified Glasgow Prognostic Score (mGPS)
Calculates the conventional 2007 modified Glasgow Prognostic Score from CRP and albumin as a systemic-inflammation prognostic group in cancer.
Glasgow Prognostic Score (Original GPS)
Calculates the original 2003 Glasgow Prognostic Score from CRP and albumin as an inflammation-based prognostic group.
Fong Clinical Risk Score (CRS)
Original 1999 MSKCC five-factor preoperative score for colorectal liver metastases considered for hepatic resection.
Original NIH-Fletcher GIST Risk Criteria (2002)
Historical four-group NIH-Fletcher consensus classification using greatest primary GIST diameter and an integer mitotic count per historical 50 high-power fields.
AFIP/Miettinen GIST Risk Table (2006)
Original 2006 AFIP/Miettinen table for historical progressive disease after resection of untreated primary GIST, using site, raw size, and mitoses per calibrated 5 mm².
Oncotype DX Colon Recurrence Score Report Interpreter
Strictly interprets a final Exact Sciences Oncotype DX Colon Recurrence Score using the prespecified QUASAR/NSABP C-07 score groups and supported report populations.
ASCO 2022 Stage II Colon High-Risk Feature Assessment
Applies the ASCO 2022 high-risk feature checklist after resection of pT3-pT4, pN0, M0 colon cancer without converting the checklist into a numerical recurrence score.
Peritoneal Surface Disease Severity Score (PSDSS)
Calculates the original three-component colorectal PSDSS from symptoms, PCI category, and joint histopathology.
GRIm Score
Original 2017 Bigot GRIm baseline prognostic score for advanced solid-tumor patients entering phase-I immune-checkpoint-therapy trials.
LIPI Score (Lung Immune)
Original 2018 Mezquita LIPI pretreatment prognostic grouping for advanced NSCLC using raw dNLR and LDH relative to the local ULN.
Lung-RADS™ v2022
Assigns ACR Lung-RADS v2022 categories for lung cancer screening LDCT using the most suspicious source-table finding.
Small Cell Lung Cancer Staging (VALSG)
Assigns the classic 1973 Veterans Administration Lung Study Group limited or extensive stage for confirmed small-cell lung cancer.
Solitary Pulmonary Nodule Malignancy Risk (Mayo)
Estimates malignancy probability for a newly discovered, radiologically indeterminate solitary pulmonary nodule using the Swensen 1997 Mayo Clinic model.
Herder Model (Pulmonary Nodule)
Estimates PET-adjusted malignancy probability for an indeterminate solitary solid pulmonary nodule using the Herder 2005 model and the full-precision Mayo probability.
Masaoka-Koga Staging (Thymoma)
Assigns the historical 1994 Masaoka-Koga surgical-pathological stage for primary thymoma from its highest confirmed extent.
Mesothelioma EORTC Prognostic Index
Original 1998 Curran EORTC weighted prognostic index for baseline malignant pleural mesothelioma.
Mesothelioma CALGB Score
Reproduces the original 1998 Herndon CALGB six-group prognostic classification for adults with advanced malignant mesothelioma treated in historical chemotherapy trials.
2021 WHO CNS5 Grade Interpreter
Interprets an explicitly pathologist-assigned CNS WHO grade from an integrated WHO CNS5 (2021) neuropathology report without deriving the grade.
RPA (Brain Metastases)
Original 1997 RTOG RPA baseline prognostic classification for adults with confirmed brain metastases.
GPA (Graded Prognostic Assessment)
Original 2008 diagnosis-agnostic GPA for pretreatment prognostic classification in adults with established brain metastases.
Original Diagnosis-Specific GPA for Brain Metastases (2012)
Interprets the original 2012 non-molecular diagnosis-specific GPA for baseline adult parenchymal brain metastases.
Tokuhashi Score Calculator — Spine Metastases Surgical Prognosis
Revised 2005 Tokuhashi score for pretreatment prognostic classification in established metastatic spinal tumors.
Tomita Score (Spine Mets)
Original 2001 Tomita score for baseline classification of established spinal metastases using tumor growth and metastatic burden.
SINS (Spinal Instability)
Original 2010 Spinal Instability Neoplastic Score for lesion-level classification of neoplastic spinal instability.
New England Spinal Metastasis Score (NESMS)
Calculates the original 2015 NESMS from the modified Bauer score, independent ambulation, and raw serum albumin at baseline in confirmed spinal metastatic disease.
Original Mirels Score for Metastatic Long-Bone Lesions (1989)
Interprets the original 1989 Mirels total for an intact metastatic long-bone lesion using four clinician-selected source categories.
Bauer Score (Bone Mets)
Original 1995 Bauer-Wedin five-factor preoperative prognostic score for surgically treated skeletal metastases.
Revised 2014 Katagiri Score
Calculates the revised 2014 Katagiri prognostic score for newly detected skeletal metastases using source-defined tumor, disease, laboratory, performance, treatment-history, and skeletal-burden categories.
FNCLCC Grade (Soft Tissue Sarcoma)
Assigns FNCLCC histologic grade from tumor differentiation, mitotic count, and tumor necrosis.
Enneking Staging (Bone/Sarcoma)
Assigns the original 1980 Enneking/MSTS surgical stage for malignant musculoskeletal sarcoma from grade, compartment, and metastasis.
HLH-2004 Diagnostic Criteria Calculator — Hemophagocytic Lymphohistiocytosis
Apply the original Histiocyte Society HLH-2004 molecular pathway and 5-of-8 diagnostic criteria with explicit handling of unassessed criteria.
HScore for Reactive HLH (2014)
Original Fardet 2014 HScore estimating the probability of adult reactive hemophagocytic syndrome from nine explicitly assessed variables.
Pediatric LCH Risk-Organ Classification
Implements the SIOPE/ERN PaedCan pediatric-onset LCH extent and risk-organ classification with explicit liver, spleen, and source-defined hematopoietic assessment.
SEER Summary Stage 2018 Extent Classification for Histiocytic Sarcoma, EOD v3.3 / NAACCR 2026
Records the source-defined localized, systemic, or unknown SEER HemeRetic extent for pathology-confirmed histiocytic sarcoma 9755/3 at initial diagnosis.
Weiss Score (Adrenal)
Original nine-criterion Weiss histopathology score for resected conventional adult adrenocortical tumors.
PASS Score (Pheochromocytoma)
Reproduces the original 2002 Thompson PASS histopathology score for a resected adrenal pheochromocytoma.
NET Grade / WHO 2019
Assigns WHO 2019 histologic grade for well-differentiated gastroenteropancreatic NETs from Ki-67 index and mitotic rate.
MASCC Risk Index
Estimate serious-complication risk in chemotherapy-related febrile neutropenia; the score does not independently determine outpatient eligibility.
CARG Toxicity Score (Geriatric)
Original 11-item CARG score for adults aged 65 years or older starting a new cytotoxic chemotherapy regimen.
CARG-BC Breast Chemotherapy Toxicity
Breast-specific CARG-BC score grouping observed grade 3-5 chemotherapy toxicity incidence in adults age 65 or older with stage I-III breast cancer.
Original CRASH Chemotherapy Toxicity Score (2012)
Source-locked pretreatment interpreter of the original CRASH hematologic, non-hematologic, and combined toxicity groups for adults age 70 or older.
G8 Screening Tool
Classic eight-item G8 screen for geriatric vulnerabilities in older adults with cancer.
CISNE Score (Febrile Neutropenia)
Predict serious complications after initial apparent stability in adults with solid tumors and outpatient-onset febrile neutropenia.
ESAS-R Calculator — Edmonton Symptom Assessment System Revised
2011 Watanabe ESAS-r nine-symptom profile for point-in-time symptom assessment in oncology and palliative care.
PaP Score (Palliative Prognosis)
Original 1999 Palliative Prognostic Score for 30-day survival grouping in terminal solid-cancer palliative care.
Palliative Prognostic Index (PPI)
Palliative Prognostic Index for published short-term survival thresholds in advanced or terminal cancer.
NCCN-IPI (Lymphoma)
NCCN-IPI prognostic stratification for newly diagnosed diffuse large B-cell lymphoma in the rituximab era.
CLL-IPI
Original CLL-IPI prognostic stratification using TP53, IGHV, beta-2 microglobulin, clinical stage, and age.
Original Continuous MIPI (Mantle Cell Lymphoma)
Calculates the original continuous MIPI prognostic score for advanced-stage mantle cell lymphoma from age, ECOG, LDH, and WBC.
IPS (Hodgkin Lymphoma)
Original 1998 Hasenclever seven-factor baseline prognostic score for locally defined advanced Hodgkin lymphoma.
GHSG and EORTC/GELA Early-Stage Classical Hodgkin Lymphoma Risk Groups
Source-specific GHSG HD10/HD11-era or EORTC/GELA H9-U baseline risk-group interpretation for early-stage classical Hodgkin lymphoma.
IPS-7 (Adult Hodgkin Lymphoma)
Original 1998 Hasenclever seven-factor baseline prognostic score for locally defined advanced Hodgkin lymphoma.
CHIPS (Childhood Hodgkin Score)
Original 2017 four-factor CHIPS baseline prognostic score for protocol-defined intermediate-risk pediatric and adolescent classical Hodgkin lymphoma.
DIPSS (Myelofibrosis)
Original all-age DIPSS prognostic stratification for confirmed primary myelofibrosis at diagnosis or reassessment.
DIPSS-Plus (Myelofibrosis)
Original 2011 Gangat DIPSS-Plus for prognostic grouping in confirmed primary myelofibrosis.
IPSSWM (Waldenström)
Original 2009 Morel IPSSWM prognostic classification for symptomatic Waldenström macroglobulinemia at first-line treatment initiation.
ELTS Score (CML)
Calculates the original ELTS baseline prognostic group for adults with newly diagnosed chronic-phase Ph-positive or BCR::ABL1-positive CML before treatment.
SANZ Risk Score (APL)
Original 2000 PETHEMA/GIMEMA three-group APL relapse-risk classification using presentation WBC and platelet counts.
HCT-CI (Transplant Risk)
Original 2005 Sorror HCT-CI for source-defined comorbidity burden before allogeneic hematopoietic cell transplantation.
R-ISS (Multiple Myeloma)
Original 2015 IMWG Revised International Staging System for baseline staging of newly diagnosed multiple myeloma.
FLIPI (Follicular Lymphoma)
Original FLIPI-1 prognostic stratification at initial follicular lymphoma diagnosis using five source-defined adverse factors.
IPSS-R for MDS
Original 2012 basic IPSS-R prognostic stratification for primary untreated myelodysplastic syndromes at diagnosis.
International Prognostic Index (IPI)
Original five-factor International Prognostic Index for prognostic stratification in aggressive non-Hodgkin lymphoma.
ALBI Score
Calculates the original 2015 Albumin-Bilirubin grade for objective prognostic assessment of liver function in hepatocellular carcinoma.
Original 2016 ALBI-T Score using LCSGJ Fifth-Edition TNM
Historical additive score combining an externally assigned original ALBI grade with an externally assigned LCSGJ fifth-edition TNM stage in treatment-naive hepatocellular carcinoma.
BCLC 2026 Hepatocellular Carcinoma Stage
Corrected BCLC 2026 stage assignment for confirmed HCC using raw tumor burden, HCC-attributable ECOG, and explicit liver-status context.
Original Hong Kong Liver Cancer Staging System (HKLC-9, 2014)
Strict stage-only interpretation of the original 2014 nine-category HKLC system for confirmed HCC.
CNLC 2024 Staging for Hepatocellular Carcinoma
Official CNLC 2024 baseline staging for confirmed hepatocellular carcinoma using ECOG status, Child-Pugh class, tumor burden, vascular invasion, and extrahepatic metastasis.
Original 2003 Japan Integrated Staging (JIS) Score
Original conventional JIS score combining an independently assigned Child-Turcotte-Pugh class with LCSGJ fourth-edition TNM stage for established hepatocellular carcinoma.
Child-Turcotte-Pugh (CTP) Score: PT or INR Variant
Calculates the standard-bilirubin Child-Turcotte-Pugh total and class from a contemporaneous adult chronic-liver-disease assessment using either PT prolongation or INR.
OPTN Calculated MELD 3.0
Strict U.S. OPTN Calculated MELD 3.0 implementation under Policy 9.1.D for candidates age 12 or older.
Milan Criteria
Classifies hepatocellular carcinoma tumor burden against the original 1996 Milan criteria.
CLIP Score
Original 1998 Cancer of the Liver Italian Program score for baseline prognosis in adults with cirrhosis and established hepatocellular carcinoma.
ACR CT/MRI LI-RADS® v2018 Diagnostic Algorithm
Strict ACR CT/MRI LI-RADS v2018 diagnostic categorization for eligible adult high-risk patients with an untreated observation without pathologic proof.
IMDC (Heng) Risk Criteria Calculator — Metastatic Renal Cell Carcinoma
Reproduces the original six-factor 2009 IMDC/Heng prognostic classification for metastatic renal cell carcinoma.
MSKCC (Motzer) Score
Reproduces the five-factor 2002 MSKCC/Motzer prognostic classification for previously untreated advanced or metastatic renal cell carcinoma.
SSIGN Score (Mayo)
Original 2002 Mayo SSIGN score for postoperative clear-cell renal cell carcinoma using 1997 TNM stage, size, grade, and necrosis.
UISS (UCLA Integrated Staging)
Classifies localized postoperative RCC using the 2002 UISS algorithm from pathological T category, Fuhrman grade, and ECOG status.
ACR BI-RADS 5th Edition Mammography Report Interpreter
Strictly interprets a radiologist-assigned ACR BI-RADS 5th Edition (2013) mammography assessment category and its source-table likelihood interval.
Original Nottingham Prognostic Index, three-group model (NPI-3, 1982)
Source-locked postoperative NPI-3 interpretation from invasive tumor size, positive axillary-node count, and Nottingham histologic grade.
CPS+EG Score (Original AJCC 6th-Edition Model)
Calculates the original 0-6 CPS+EG score from AJCC 6th-edition presenting clinical stage, final post-neoadjuvant yp stage, ER status, and nuclear grade.
Allred Score for ER/PR
Original 1998 Allred score for separate pathologist assessment of ER or PR nuclear immunohistochemistry in breast carcinoma.
New Magee Equation 1 (2013 pathology-based estimated recurrence score)
Full-precision New Magee Equation 1 estimate from complete source-compatible surgical pathology; explicitly not an actual Oncotype DX result.
Residual Cancer Burden (RCB)
Original six-input Residual Cancer Burden index for surgical pathology assessment after neoadjuvant chemotherapy.
CTS5 Late Breast Cancer Recurrence
Calculates the final 2018 combined-cohort CTS5 group for distant recurrence during years 5-10 after 5 years of endocrine therapy.
NCI BCRAT (Gail Model)
Estimates 5-year and risk-to-age-90 invasive breast cancer probability using the NCI BCRAT v4.1 competing-risk algorithm.
Oncotype DX Breast Recurrence Score Report Interpreter
Interpret a final externally reported Exact Sciences 21-gene Breast Recurrence Score within separate TAILORx node-negative and RxPONDER 1-3-node evidence contexts.
MammaPrint FFPE Microarray K201902 Reported MPI Interpreter
Strictly interprets an externally reported MammaPrint FFPE microarray MPI and matching report category using FDA K201902 and the unchanged K141142 thresholds.
Prosigna FDA K130010 Reported ROR Risk-Category Interpreter
Interprets an externally generated integer Prosigna ROR score using only the FDA K130010 node-negative and 1-3-positive-node category table.
EndoPredict EPclin Reported Risk-Class Interpreter, EPRG v4.2 (2025)
Interprets a final externally generated one-decimal EPclin score from Eurobio EndoPredict Report Generator v4.2 (2025).
D'Amico Risk Classification
Original 1998 D'Amico three-group classification using pretreatment PSA, biopsy Gleason score, and clinical T stage.
Johns Hopkins Epstein T1c Pretreatment Criteria (1994 derivation; 1997 operational thresholds)
Strict historical interpreter of the four 1997 operational thresholds used after the 1994 Johns Hopkins cT1c derivation.
PI-RADS® v2.1 Assessment Category Interpreter
Interprets an existing radiologist-assigned 2019 ACR-ESUR-AdMeTech PI-RADS v2.1 category without deriving or changing it.
Gleason Score & WHO/ISUP Grade Group
Converts two ordered Gleason patterns already reported by pathology into the Gleason score and WHO/ISUP Grade Group.
UCSF-CAPRA Score
Original 2005 preoperative UCSF-CAPRA score for biochemical recurrence risk stratification after radical prostatectomy.
CAPRA-S Score (Post-Surgical)
Original 2011 UCSF CAPRA-S postoperative score using preoperative PSA and radical-prostatectomy pathology.
Decipher Prostate Localized Reported Score Interpreter
Interprets an externally reported continuous Decipher Prostate localized Biopsy v14.0 or RP v12.0 score using the shared three-band report cut-points.
MDxHealth Genomic Prostate Score (GPS) Report Interpreter, formerly Oncotype DX GPS
Interprets a final externally generated MDxHealth GPS integer within the matching current low-risk or high-risk report family.
ProMark Published Biomarker Risk Score Interpreter (2015, 0-1 scale)
Interpret an externally generated 0-1 score from the final eight-protein biopsy assay published by Blume-Jensen et al. in 2015.
EORTC 2006 NMIBC Recurrence & Progression Tables
Original EORTC 2006 recurrence and progression probabilities for papillary Ta/T1 bladder cancer after TURBT.
CUETO Risk Score (BCG-Treated)
Original 2009 CUETO recurrence and progression scores for BCG-treated Ta/T1 non-muscle-invasive bladder cancer.
EAU 2021 NMIBC Prognostic Factor Risk Groups
WHO 2004/2016 or WHO 1973 progression-risk grouping after adequate TURBT.
Original 1997 IGCCCG Prognostic Classification
Applies the original 1997 IGCCCG categorical classifier and reports clearly labeled 2021 cohort outcomes for the matched group.
EAU 2026 Clinical Stage I NSGCT LVI Risk Group
Strict interpreter of the EAU 2026 lymphovascular-invasion risk grouping for postpubertal clinical Stage I nonseminomatous germ cell tumors after radical inguinal orchiectomy.
FIGO-Modified WHO Gestational Trophoblastic Neoplasia Risk Score 2026
Strict FIGO 2026 anatomical stage plus seven-factor modified WHO GTN score for initial pretreatment assessment.
RMI (Risk of Malignancy Index)
Original 1990 Jacobs RMI-I for preoperative discrimination of malignant versus benign pelvic masses.
ROMA Score (Ovarian)
Roche Elecsys ROMA probability and assay-specific risk classification for women presenting with a pelvic mass.
AGO Score for Complete Secondary Cytoreduction (DESKTOP III)
Neutral interpreter of the three operational AGO criteria used in DESKTOP III, supported by DESKTOP II, for first platinum-sensitive recurrence of epithelial ovarian cancer.
Tian iMODEL for Ovarian Cancer Recurrence
Original 2012 six-factor Tian score for complete secondary cytoreduction in first platinum-sensitive recurrent epithelial ovarian cancer.
ACR O-RADS US v2022 Per-Lesion Calculator
Strict per-lesion ACR O-RADS Ultrasound v2022 (November 2022) decision tree with exact lexicon, risk intervals, and context-qualified management.
ESGO/ESTRO/ESP 2021 Endometrial Risk Groups - Molecular Classification Unknown
Source-locked FIGO 2009 postoperative prognostic-group interpreter for adult endometrial carcinoma when molecular classification is unknown or unavailable.
Mayo Criteria (Endometrial)
Applies the original 2000 Mariani Mayo low-risk criteria after confirming endometrioid histology, gross-disease status, and adequate surgicopathologic assessment.
Sedlis Criteria (Cervical)
Applies the original 1999 GOG-92 Sedlis postoperative intermediate-risk combinations after confirming the historical eligibility context.
Moore/GOG Cervical Prognostic Index
Reproduces the original 2010 five-factor GOG prognostic index for measurable stage IVB, persistent, or recurrent cervical carcinoma in its historical cisplatin-combination context.
Melanoma SLNB Guidance Interpreter, AJCC8 and ESMO 2024
Interprets an AJCC8 cutaneous-melanoma T category and the matched ESMO 2024 sentinel-lymph-node-biopsy guidance row without estimating nodal probability.
MACIS Score (Thyroid)
Original 1993 Mayo Clinic postoperative MACIS prognostic score for papillary thyroid carcinoma.
2025 ATA Estimated Risk of Structural Recurrence for Adult Differentiated Thyroid Cancer
Strict interpreter of the 2025 ATA initial postoperative structural-recurrence categories using raw pathology, nodal, margin, invasion, and metastatic findings.
About OncoToolkit: Your Comprehensive Oncology Calculator Resource
OncoToolkit provides healthcare professionals with a comprehensive suite of evidence-based oncology calculators, staging systems, and prognostic tools. Our platform supports clinical decision-making across all major cancer types, from initial diagnosis through treatment planning and follow-up care.
Comprehensive Cancer Staging & Prognosis Tools
Access validated scoring systems including ECOG and Karnofsky Performance Status for functional assessment, Child-Pugh and ALBI scores for liver function evaluation, and tumor-specific staging calculators following AJCC/UICC guidelines. Our tools cover breast cancer (Oncotype DX, NPI), prostate cancer (Gleason, CAPRA), lung cancer (TNM staging, GPA), and many more.
Treatment Decision Support
Make informed treatment decisions with calculators designed to assess treatment eligibility, predict response, and evaluate toxicity risk. From chemotherapy dosing based on BSA calculations to immunotherapy eligibility assessment, our tools help optimize patient outcomes while minimizing adverse events.
Evidence-Based Clinical Tools
Every calculator on OncoToolkit is based on peer-reviewed research and validated in clinical practice. We provide transparent methodology with references to original publications, ensuring you understand the evidence behind each tool. Explore our oncology glossary for terminology definitions and video tutorials about how to use this app.
OncoToolkit is for educational and clinical decision support purposes only. Always verify results with current clinical guidelines and institutional protocols.